Cargando…

Management and Outcomes of COVID – 19 Associated Cerebral Venous Sinus Thrombosis

BACKGROUND: Systemic hyper-coagulabilty leading to micro and macro thrombosis is a known complication of Coronavirus disease – 2019(COVID -19). The postulated mechanism appears to be the viral activation of endothelium, triggering the coagulation pathways. Thrombosis of the cerebral veins and sinuse...

Descripción completa

Detalles Bibliográficos
Autores principales: Miraclin T, Angel, Aaron, Dr. Sanjith, Sivadasan, Ajith, Benjamin, Kenneth, Harshad, Vanjare, Nair, Shalini, Abhilash, KPP, AT, Prabhakar, Mathew, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743463/
https://www.ncbi.nlm.nih.gov/pubmed/35091267
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2022.106306
_version_ 1784629910781820928
author Miraclin T, Angel
Aaron, Dr. Sanjith
Sivadasan, Ajith
Benjamin, Kenneth
Harshad, Vanjare
Nair, Shalini
Abhilash, KPP
AT, Prabhakar
Mathew, Vivek
author_facet Miraclin T, Angel
Aaron, Dr. Sanjith
Sivadasan, Ajith
Benjamin, Kenneth
Harshad, Vanjare
Nair, Shalini
Abhilash, KPP
AT, Prabhakar
Mathew, Vivek
author_sort Miraclin T, Angel
collection PubMed
description BACKGROUND: Systemic hyper-coagulabilty leading to micro and macro thrombosis is a known complication of Coronavirus disease – 2019(COVID -19). The postulated mechanism appears to be the viral activation of endothelium, triggering the coagulation pathways. Thrombosis of the cerebral veins and sinuses (CVT), a potentially serious condition, has been increasingly reported with COVID – 19 infection. In this clinical study we attempt to describe the clinical profile, investigations and outcomes of patients with COVID- 19 associated CVT. METHODS: This is a single center prospective observational study from South India. The study included patients (aged >18 years) with concomitant COVID infection and CVT. The clinical, laboratory, imaging characteristics, management and outcomes were described and compared with COVID negative CVT patients. RESULTS: Out of 97 cases of CVT treated at our center during the first and second waves of the COVID pandemic 11/97 (11%) were COVID related CVT. Among these 11 patients, 9 (81%) had presented with only CVT related symptoms and signs and were tested positive for COVID - 19 infection during the pre-hospitalization screening. Respiratory symptoms were absent in 90% of the patients. Headache (100%) and seizures (90%) were the common presenting symptoms. The median time to diagnosis was 6 hours, from presentation to the emergency department. Transverse sinus was involved 10/11 (90%) and majority of them (9/11) had Haemorrhagic Venous Infarction (HVI). Acute inflammatory markers were elevated in comparison with non COVID CVT patients, with the mean serum D-dimer being 2462.75 ng/ml and the C-reactive protein was 64.5 mg/dl. Three patients (30%) underwent decompressive hemicraniectomy (DHC) because of large hemispheric HVI. All patients survived in the COVID CVT group while the mortality in the non COVID group was 4%. At 6 months follow up excellent outcome (modified Rankin Scale (mRS) score of 0–2) was noted equally in both groups. CONCLUSIONS: Symptoms and signs of CVT may be the only presentation of COVID-19 infection. Prompt recognition and aggressive medical management including DHC offers excellent outcomes.
format Online
Article
Text
id pubmed-8743463
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-87434632022-01-10 Management and Outcomes of COVID – 19 Associated Cerebral Venous Sinus Thrombosis Miraclin T, Angel Aaron, Dr. Sanjith Sivadasan, Ajith Benjamin, Kenneth Harshad, Vanjare Nair, Shalini Abhilash, KPP AT, Prabhakar Mathew, Vivek J Stroke Cerebrovasc Dis Short Communication BACKGROUND: Systemic hyper-coagulabilty leading to micro and macro thrombosis is a known complication of Coronavirus disease – 2019(COVID -19). The postulated mechanism appears to be the viral activation of endothelium, triggering the coagulation pathways. Thrombosis of the cerebral veins and sinuses (CVT), a potentially serious condition, has been increasingly reported with COVID – 19 infection. In this clinical study we attempt to describe the clinical profile, investigations and outcomes of patients with COVID- 19 associated CVT. METHODS: This is a single center prospective observational study from South India. The study included patients (aged >18 years) with concomitant COVID infection and CVT. The clinical, laboratory, imaging characteristics, management and outcomes were described and compared with COVID negative CVT patients. RESULTS: Out of 97 cases of CVT treated at our center during the first and second waves of the COVID pandemic 11/97 (11%) were COVID related CVT. Among these 11 patients, 9 (81%) had presented with only CVT related symptoms and signs and were tested positive for COVID - 19 infection during the pre-hospitalization screening. Respiratory symptoms were absent in 90% of the patients. Headache (100%) and seizures (90%) were the common presenting symptoms. The median time to diagnosis was 6 hours, from presentation to the emergency department. Transverse sinus was involved 10/11 (90%) and majority of them (9/11) had Haemorrhagic Venous Infarction (HVI). Acute inflammatory markers were elevated in comparison with non COVID CVT patients, with the mean serum D-dimer being 2462.75 ng/ml and the C-reactive protein was 64.5 mg/dl. Three patients (30%) underwent decompressive hemicraniectomy (DHC) because of large hemispheric HVI. All patients survived in the COVID CVT group while the mortality in the non COVID group was 4%. At 6 months follow up excellent outcome (modified Rankin Scale (mRS) score of 0–2) was noted equally in both groups. CONCLUSIONS: Symptoms and signs of CVT may be the only presentation of COVID-19 infection. Prompt recognition and aggressive medical management including DHC offers excellent outcomes. Elsevier Inc. 2022-04 2022-01-10 /pmc/articles/PMC8743463/ /pubmed/35091267 http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2022.106306 Text en © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Short Communication
Miraclin T, Angel
Aaron, Dr. Sanjith
Sivadasan, Ajith
Benjamin, Kenneth
Harshad, Vanjare
Nair, Shalini
Abhilash, KPP
AT, Prabhakar
Mathew, Vivek
Management and Outcomes of COVID – 19 Associated Cerebral Venous Sinus Thrombosis
title Management and Outcomes of COVID – 19 Associated Cerebral Venous Sinus Thrombosis
title_full Management and Outcomes of COVID – 19 Associated Cerebral Venous Sinus Thrombosis
title_fullStr Management and Outcomes of COVID – 19 Associated Cerebral Venous Sinus Thrombosis
title_full_unstemmed Management and Outcomes of COVID – 19 Associated Cerebral Venous Sinus Thrombosis
title_short Management and Outcomes of COVID – 19 Associated Cerebral Venous Sinus Thrombosis
title_sort management and outcomes of covid – 19 associated cerebral venous sinus thrombosis
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743463/
https://www.ncbi.nlm.nih.gov/pubmed/35091267
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2022.106306
work_keys_str_mv AT miraclintangel managementandoutcomesofcovid19associatedcerebralvenoussinusthrombosis
AT aarondrsanjith managementandoutcomesofcovid19associatedcerebralvenoussinusthrombosis
AT sivadasanajith managementandoutcomesofcovid19associatedcerebralvenoussinusthrombosis
AT benjaminkenneth managementandoutcomesofcovid19associatedcerebralvenoussinusthrombosis
AT harshadvanjare managementandoutcomesofcovid19associatedcerebralvenoussinusthrombosis
AT nairshalini managementandoutcomesofcovid19associatedcerebralvenoussinusthrombosis
AT abhilashkpp managementandoutcomesofcovid19associatedcerebralvenoussinusthrombosis
AT atprabhakar managementandoutcomesofcovid19associatedcerebralvenoussinusthrombosis
AT mathewvivek managementandoutcomesofcovid19associatedcerebralvenoussinusthrombosis